Edition:
India

Ra Pharmaceuticals Inc (RARX.OQ)

RARX.OQ on NASDAQ Stock Exchange Global Market

23.40USD
22 May 2019
Change (% chg)

$0.10 (+0.43%)
Prev Close
$23.30
Open
$23.51
Day's High
$24.14
Day's Low
$23.33
Volume
94,803
Avg. Vol
141,249
52-wk High
$27.62
52-wk Low
$5.88

Latest Key Developments (Source: Significant Developments)

Ra Pharmaceuticals Q4 Loss Per Share $0.47
Thursday, 7 Mar 2019 

March 7 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE ESTIMATE $-0.52 -- REFINITIV IBES DATA.QTRLY REVENUE $2.5 MILLION.  Full Article

Ra Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock
Wednesday, 12 Dec 2018 

Dec 11 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.RA PHARMACEUTICALS- PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 8,387,097 SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $15.50 PER SHARE.  Full Article

Ra Pharmaceuticals Announces Positive Top-Line Data From Phase 2 Trial Of Zilucoplan
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2 TRIAL OF ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS.RA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2 TRIAL OF ZILUCOPLAN IN PATIENTS WITH GENERALIZED MYASTHENIA GRAVIS.RA PHARMACEUTICALS INC - CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT REDUCTIONS IN BOTH QMG AND MG-ADL.RA PHARMACEUTICALS INC - PRIMARY AND KEY SECONDARY ENDPOINTS IN STUDY MET IN A BROAD SPECTRUM OF PATIENTS WITH GMG.RA PHARMACEUTICALS - PLANS TO ENGAGE WITH FDA IN H1 2019 REGARDING DESIGN OF A PHASE 3 TRIAL FOR 0.3 MG/KG DOSE OF ZILUCOPLAN VERSUS PLACEBO IN GMG PATIENTS.  Full Article

Ra Pharma Announces Positive Results From Phase 1B Pharmacokinetic Study Of Zilucoplan In Patients With Renal Impairment
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 1B PHARMACOKINETIC STUDY OF ZILUCOPLAN (RA101495 SC) IN PATIENTS WITH RENAL IMPAIRMENT.RA PHARMACEUTICALS INC - PLANS TO INITIATE A GLOBAL, PIVOTAL, SINGLE-ARM PHASE 3 TRIAL IN TREATMENT-NAÏVE PNH PATIENTS DURING FIRST HALF OF 2019.RA PHARMACEUTICALS-PK PROFILE OF ZILUCOPLAN WAS CONSISTENT ACROSS BOTH GROUPS, WITH EXPOSURES SIMILAR IN RENALLY-IMPAIRED PATIENTS, HEALTHY VOLUNTEERS.RA PHARMACEUTICALS INC - THERE WERE NO ADVERSE EVENTS REPORTED IN RESULTS.  Full Article

Ra Pharmaceuticals Q2 Loss Per Share $0.49
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND ANNOUNCES EARLY COMPLETION OF ENROLLMENT IN GMG PHASE 2 PROGRAM.Q2 LOSS PER SHARE $0.49.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.COMPANY EXPECTS THAT ITS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS THROUGH END OF 2019.AS OF JUNE 30, 2018, RA PHARMA REPORTED TOTAL CASH AND CASH EQUIVALENTS OF $95.1 MILLION.TOP-LINE DATA FOR PHASE 2 TRIAL OF RA101495 SC NOW EXPECTED AROUND YEAR-END 2018.  Full Article

Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Ra Pharmaceuticals Inc ::RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS.RA PHARMACEUTICALS INC - TOPLINE DATA FROM SECOND CLINICAL INDICATION OF RA101495 SC EXPECTED FIRST HALF OF 2019.  Full Article

Ra Pharmaceuticals posts Q3 loss of $0.68 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Ra Pharmaceuticals Inc :Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.68.Q3 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.As of September 30, 2017, Ra Pharma reported total cash and equivalents of $84.1 million​.Company expects that its cash and cash equivalents will be sufficient to fund operations through end of 2018​.  Full Article

Ra Pharmaceuticals files for mixed shelf offering of up to $250 million
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Ra Pharmaceuticals Inc :Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing‍​.  Full Article